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A B S T R A C T
Purpose
Increased mammographic density is associated with increased breast cancer risk and reduced
sensitivity of screening mammography and is related to hormone exposure. However, the effects
of conjugated equine estrogens (CEEs) alone on mammographic density in diverse racial/ethnic
populations are not established. We examined the effect of CEE alone on mammographic density
in a subsample of the Women’s Health Initiative (WHI) clinical trial participants.
Patients and Methods
In the WHI trial, women were randomly assigned to daily CEE 0.625 mg or placebo. The effect of
CEE on mammographic percent density was determined over 1 and 2 years in a stratified random
sample of 435 racially and ethnically diverse participants from 15 of 40 WHI clinics.
Results
Use of CEE resulted in mean increase in mammographic percent density of 1.6 percentage points
(95% CI, 0.8 to 2.4) at year 1 compared with a mean decrease of 1.0 percentage point (95% CI,
1.7 to 0.4) in the placebo group (P  .001). The effect persisted for 2 years, with a mean
increase of 1.7 percentage points (95% CI, 0.7 to 2.7) versus a mean decrease of 1.2 percentage
points (95% CI, 1.8 to 0.5; P  .001) in the hormone and placebo groups, respectively. These
effects were greater in women age 60 to 79 years (P  .03 for interaction across age).
Conclusion
Use of CEE results in a modest but statistically significant increase in mammographic density that
is sustained over at least a 2-year period. The clinical significance of the CEE effect on
mammographic density remains to be determined.
J Clin Oncol 27:6135-6143. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Mammographic density is positively associated with
breast cancer risk.1-5 The decrease in mammo-
graphic density after menopause6 suggests a hor-
monal influence, and observational and short-term
clinical trials have shown an association between
menopausal hormone therapy use and increased
mammographic density.7-11 A relationship between
an intervention’s influence on breast density and its
influence on breast cancer risk has been proposed.12
However, the effects of menopausal hormone ther-
apy on breast density in racial/ethnic populations
and duration effects are not established.
The Women’s Health Initiative (WHI) re-
ported that combined conjugated equine estrogens
(CEEs) plus medroxyprogesterone acetate (MPA)
doubled mammographic density9 and significantly
increased breast cancer incidence in postmeno-
pausal women with no prior hysterectomy.13 How-
ever, CEE alone did not increase breast cancer
incidence but suggested a decrease in incidence.14
We evaluated the effect of CEE alone on mammo-
graphic density over 2 years in a randomly identified
subsample of WHI CEE clinical trial participants,




The WHI CEE-alone trial enrolled 10,739 post-
menopausal women from 1993 to 1998 at 40 clinical cen-
ters.15,16 The study was approved by human subjects
committees at each institution. Briefly, women recruited
by multiple methods17 were eligible if they were between
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age 50 and 79 years at entry and were postmenopausal, had prior hysterec-
tomy, and provided written informed consent. Women with prior breast
cancer or those with medical conditions likely to result in death within 3 years
were excluded. Prior menopausal hormone use required a 3-month washout
period before baseline testing (mammographic density has been shown to
decrease within a few weeks of stopping menopausal hormone use).18 Before
random assignment, 46% had used estrogen alone and 5% had used estrogen
plus progesterone. Baseline mammogram and clinical breast examination
within 6 months before random assignment were required. Women were
randomly assigned to daily CEE 0.625 mg in a single tablet (Premarin; Wyeth
Ayerst, Philadelphia, PA), or an identical-appearing placebo. Participants had
follow-up clinic visits every 6 months, where pill adherence was obtained from
pill counts, potential adverse effects were determined, and exposure covariates
were updated.14 During follow-up, women received annual clinical breast
examinations and screening mammograms. After a mean of 6.8 years of
follow-up, the trial was stopped early on the basis of an increased risk of stroke
and no reduction in coronary heart disease risk.15
Mammogram Density Ancillary Study
Fifteen of 40 WHI clinical centers participated in the separately funded
Mammogram Density Ancillary Study. The Clinical Coordinating Center
identified a stratified random sample of women in the WHI CEE trial to be
approached for participation, with the goal of sampling 150 women within
each of the following groups: African Americans, Asian/Pacific Islanders, His-
panics, and non-Hispanic whites. A 10% over-sample was selected to allow for
those electing not to participate. Inclusion criteria included availability of a
prerandomization (baseline) mammogram plus at least one follow-up mam-
mogram after 1 or 2 years. Sample size was based on the primary study
aim—an anticipated mammographic density difference of 8% (standard de-
viation [SD], 10%) between CEE and placebo groups after 1 year of treatment,
with the assumption of 33% loss to follow-up/nonadherence. A secondary aim
of the study was to determine whether a hormone effect exists within different
race/ethnic groups; therefore, the study was powered to assess effects on
density within the four race/ethnic groups. Two years of follow-up was the
time frame chosen to determine the longer-term effects of CEE on density.
Data Collection
Our mammographic density measurement methods have been previ-
ously published9 and have been validated across all mammographic density
types (fatty to dense) and all age groups, including older women.19 Briefly,
films were digitized on a Lumisys 85 laser digitizer (Eastman Kodak Company,
Rochester, NY), and the files were converted to bitmap format suitable for
display and density measurement. Mammographic density was assessed with a
previously validated20 computer-assisted interactive thresholding technique
using Imaging Research Program software (Sunnybrook Health Science Cen-
tre, Toronto, Ontario, Canada). After identifying thresholds, the software was
used to calculate the total breast area, the total area of density, and percent
mammographic density (ratio of dense breast area to total breast area). The
right craniocaudal view was measured, unless it was unavailable, in which case
the left craniocaudal view was used. Measurements were done in batches of 30
to 40 films selected without regard to whether they were before random
assignment or follow-up films, and the films were sorted in random order.
Baseline and follow-up films from the same participant were not necessar-
ily included in the same batch, and batches for each observer were gener-
ated independently.
Two trained investigators (C.M. and J.D.P.), blind to treatment arm and
film time sequence, performed density measurements on all films, with high
reliability (intraclass correlation coefficients  0.92). We calculated percent
density for each film as the mean of both investigators’ measures for that film.
Statistical Methods
All primary analyses focused on changes in mean percent density at
baseline compared with years 1 and 2 by CEE random assignment. Mixed-
effects (repeated measures) models were used to formally test whether treat-
ment affected longitudinal density change, whether this relationship depended
on race/ethnicity, mammogram sequence (baseline or follow-up), or baseline
characteristics. Log-transformed percent density values were used in these
models to reduce skewness of the percent density data. We also present differ-
ences over time (eg, year 1 – baseline) that are not skewed. Change in weight
and physical activity were determined at each follow-up interval chosen be-
cause of their potential associations with mammographic density.21 We as-
sessed several baseline characteristics as potential effect modifiers, including
age (50 to 59, 60 to 69, and 70 to 79 years), race/ethnicity (non-Hispanic white,
African American, white), body mass index (BMI;  25.0, 25.0 to 29.9,  30
kg/m2), smoking status (past, never, current), and parity (0, 1 to 2, 3 to 4,  5),
and Gail risk score22 (5-year risk,  1.7% v  1.7% [the cutoff used in the
Participants randomly assigned
(N = 10,739)
Randomly assigned to CEE
(n = 5, 310)
Randomly assigned to placebo
(n = 5,429)
Women located at participating clinics
(n = 2, 346)
Women located at participating clinics
(n = 2,427)
Eligible for the mammogram
density ancillary study
(n = 234)

































Fig 1. Flow diagram of the Mammogram
Density Ancillary Study of the Conjugated
Equine Estrogen (CEE) Component of the
Women’s Health Initiative Study.
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breast cancer chemoprevention trials]23,24). Statistical significance of interac-
tions between random assignment and baseline characteristics was judged by a
Bonferroni-corrected alpha to account for 19 tests (.05/19  .003). CIs, based
on the t distribution, are presented for changes in mammographic percent
density. Comparisons of baseline characteristics by random assignment were
made by 2 tests of association. All primary analyses were based on the
intention-to-treat principle, and all statistical tests were two-sided.
RESULTS
Demographics
A total of 498 women in the WHI CEE-alone clinical trial were
randomly selected for participation in the Mammogram Density An-
cillary Study. Forty declined participation, 458 were eligible and con-
sented, and mammograms were received and digitized for 438. Three
women developed invasive breast cancer during the study period and
were excluded, resulting in 435 (209 CEE, 226 placebo) participants
(Fig 1). Baseline mammograms were available within 6 months before
random assignment for all except three women whose baseline mam-
mograms occurred more than 6 months before random assignment
(mean time from baseline mammogram to random assignment was
367.3 days; SD, 187.1 days). Two of the women reported never using
hormone therapy before entering the trial, and one reported prior use.
These women were included in the analysis. Including these three
women in the analysis, the mean time between baseline mammogram
and random assignment was 45.4 days (SD, 35.9 days), and excluding
them it was 43.2 days (SD, 20.2 days).
The mean age of participants was 62.2 years (SD, 8.0 years).
Ancillary study participants were younger, more likely to be black or
Hispanic (by design), fewer years past menopause, less likely to have
used hormone therapy, less physically active, reporting less alcohol
consumption, and more likely to have never smoked (all P  .01; data
Table 1. Baseline Characteristics of the 435 Women in the Women’s Health
Initiative Mammogram Density Ancillary Study, CEE Trial







PNo. % No. %
Age group at screening, years .36
50-59 74 35.4 94 41.6
60-69 87 41.6 89 39.4
70-79 48 23.0 43 19.0
Ethnicity .21
White 91 43.5 84 37.2
Black 80 38.3 106 46.9
Hispanic 37 17.7 33 14.6
Asian/Pacific Islander 1 0.5 3 1.3
Education .69
High school diploma/GED or less 66 32.0 79 35.4
School after high school 93 45.1 92 41.3
College or higher 47 22.8 52 23.3
Income, $ .73
 35,000 119 60.7 131 62.4
 35,000 77 39.3 79 37.6
Years since menopause .14
 5 24 13.7 18 9.7
5- 10 23 13.1 20 10.8
10- 15 27 15.4 19 10.2
 15 101 57.7 129 69.4
Years since hysterectomy .06
 18 66 31.9 61 27.2
18- 25 60 29.0 89 39.7
 25 81 39.1 74 33.0
Age at menarche, years .97
 12 103 49.3 110 49.1
 12 106 50.7 114 50.9
No. of term pregnancies .22
Never pregnant/never had term
pregnancy 20 9.8 22 9.8
1-2 53 25.9 72 32.1
3-4 88 42.9 75 33.5
5 44 21.5 55 24.6
Duration of oral contraceptive use, years .65
Nonuser 132 63.2 132 58.4
 5 48 23.0 55 24.3
5- 10 15 7.2 23 10.2
10 14 6.7 16 7.1
Lifetime HRT duration, years .84
Never used 128 61.2 137 60.6
 5 41 19.6 49 21.7
 5 40 19.1 40 17.7
Years since last HRT use .55
Never used HRT 128 61.2 137 60.6
Current user/ 1 30 14.4 26 11.5
 1 51 24.4 63 27.9
Family history of breast cancer (female) 31 16.1 28 13.1 .39
Prior bilateral oophorectomy 69 35.9 76 38.0 .67
BMI, kg/m2 .59
Normal ( 25.0) 36 17.2 36 16.1
Overweight (25.0-29.9) 74 35.4 71 31.7
Obese ( 30.0) 99 47.4 117 52.2
(continued in next column)
Table 1. Baseline Characteristics of the 435 Women in the Women’s Health
Initiative Mammogram Density Ancillary Study, CEE Trial







PNo. % No. %
Physical activity (METs/wk) .83
Lower tertile 98 51.9 109 52.4
Middle tertile 54 28.6 63 30.3
Upper tertile 37 19.6 36 17.3
Smoking .06
Never smoked 116 55.5 128 57.4
Past smoker 73 34.9 60 26.9
Current smoker 20 9.6 35 15.7
Alcohol intake, g/d .64
Nondrinker 125 62.8 128 59.8
 2.7 38 19.1 49 22.9
 2.7 36 18.1 37 17.3
NOTE. There were no statistically significant differences between treatment
arms. Categories were chosen on the basis of distribution of the variable in the
entire Women’s Health Initiative data set.
Abbreviations: CEE, conjugated equine estrogen; GED, General Equivalency
Diploma; HRT, hormone replacement therapy; BMI, body mass index; MET,
metabolic equivalent tasks.
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not shown), compared with the overall trial participants. Most ancil-
lary study participants were non-Hispanic white (40.2%) or African
American (42.8%), 16.1% were Hispanic, and 0.9% were Asian/Pa-
cific Islander (Table 1). There were no statistically significant baseline
differences (P  .05) between CEE and placebo participants on demo-
graphic and health factors. However, several factors differed between
treatment groups by  5% including age, ethnicity, years since meno-
pause, years since hysterectomy, parity, oral contraception use, BMI,
and smoking. Therefore, these factors were evaluated as potential
confounders in analyses.
All participants had at least one, and 93% had two, follow-up
mammograms. Mean time was 1.2 years (SD, 0.4 years) between the
baseline and first follow-up mammogram, and 1.1 years (SD, 0.3
years) between the first and second follow-up mammograms. Eleven
women developed breast cancer from the end of the mammogram
density measurement period to the end of the trial.
Baseline Mammographic Percent Density
Baseline mammographic percent density ranged between 0%
and 69.4% with a mean of 7.3% (95% CI, 6.4% to 8.2%) and similar
distributions within each treatment group (mean, 6.8%; 95% CI, 5.6%
to 8.0% in CEE; and mean, 7.7%; 95% CI, 6.3% to 9.0% in placebo;
P  .80; Table 2). BMI was inversely related to baseline mammo-
graphic percent density, with overweight women having lower base-
line percent density (P  .001; data not shown). Age had modest
inverse relationships with percent density (P  .02; data not shown).
Baseline percent density differed slightly, but not statistically signifi-
cantly, among the four ethnic groups (P  .11). Mean percent density
was 7.7% (median, 6.8%) for the four Asian-American women, 9.7%
(median, 5.5%) for the 70 Hispanics, 6.2% (median, 2.8%) for the 175
non-Hispanic whites, and 7.3% (median, 3.7%) for the 186 African
Americans. After adjusting for age and BMI, these slight differences
remained (P  .09). Women who had used menopausal hormone
therapy within 6 months before random assignment (eg, just before
the required 3-month washout period; n  38) had a mean percent
density of 7.2% (95% CI, 4.4% to 10.0%) compared with 7.3% (95%
CI, 6.3% to 8.2%) for nonusers. Adjustment for age and BMI did not
change these results.
Effect of CEEs on Mammographic Percent Density
After 1 year, women in the CEE group had a mean percent
density increase of 1.6 percentage points (95% CI, 0.8 to 2.4) com-
pared with a mean 1.0 percentage point decrease (95% CI, 1.7 to
0.4) in the placebo group (P .001; Table 2). The increase in density
with CEE use persisted to year 2, with a mean increase of 1.7 percent-
age points (95% CI, 0.7 to 2.7) from baseline compared with a mean
decrease of 1.2 percentage points (95% CI, 1.8 to 0.5) in the
placebo group (P  .001). The increase in density from year 1 to year
2 among CEE users was not statistically significant (P  .44). Relative
to baseline, 56% and 55% of CEE-treated participants experienced an
increase in percent density at year 1 and year 2, respectively (data
not shown).
Effect of Adherence to Study Medications
To adjust for study medication adherence, percent density mea-
surements at follow-up were censored when a participant became
nonadherent (stopped taking study drugs, used  80% of study drugs
over a 6-month interval or, if in the placebo group, started nonproto-
col hormone therapy). The compliance effect of CEE was similar to
that shown in the intention-to-treat analyses. Among women who
were adherent to treatment, the CEE group had a mean of 1.6 percent-
age points (95% CI, 0.6 to 2.5) increase at year 1 versus a 0.9 percentage
points (95% CI, 1.6 to 0.2) decrease in placebo-treated women
(Table 2). While percent density decreased by a mean 0.4 percentage
points (95% CI, 1.2 to 2.1) from year 1 to year 2 among women on
CEE who became nonadherent within the first year of the trial, it was
not statistically significant.
Subgroup Analyses
CEE-related increase in percent density was consistent between
non-Hispanic white and African American women, while no increase
in percent density with CEE versus placebo was observed in Hispanic
Table 2. MPD at Baseline, Year 1, and Year 2, by Treatment Assignment
Measurement
CEE MPD Placebo MPD
P  P †No. Median Mean 95% CI No. Median Mean 95% CI
ITT
Baseline 209 3.4 6.8 5.6 to 8.0 226 3.4 7.7 6.3 to 9.0 .80
Year 1 209 4.6 8.4 7.2 to 9.7 226 3.1 6.6 5.5 to 7.8
Year 2 193 5.2 8.8 7.5 to 10.1 213 2.9 6.6 5.4 to 7.8
Year 1baseline 209 0.2 1.6 0.8 to 2.4 226 0.2 1.0 1.7 to 0.4  .001  .001
Year 2baseline 193 0.3 1.7 0.7 to 2.7 213 0.3 1.2 1.8 to 0.5  .001
Adjusted for adherence
Baseline 209 3.4 6.8 5.6 to 8.0 226 3.4 7.7 6.3 to 9.0
Year 1 149 5.3 8.8 7.3 to 10.4 184 3.0 6.3 5.1 to 7.6
Year 2 113 5.9 9.1 7.3 to 10.8 138 2.9 6.4 5.0 to 7.8
Year 1baseline 149 0.2 1.6 0.6 to 2.5 184 0.2 0.9 1.6 to 0.2 .002  .001
Year 2baseline 113 0.5 1.8 0.6 to 3.1 138 0.3 0.7 1.4 to 0.1  .001
Abbreviations: MPD, mammographic percent density; CEE, conjugated equine estrogen; ITT, intention to treat.
P value of main effect of CEE, by visit, is based on a two-sided t test from a repeated measures model with log (percent density  0.001) as the response. All
statistical tests were two-sided.
†P value of overall main effect of CEE at follow-up is based on an F test from a repeated measures model with log (percent density  0.001) as the response.
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Table 3. MPD at Baseline, Year 1, and Year 2, by Baseline Characteristics and Treatment Assignment
Characteristic
CEE MPD Placebo MPD
P No. Median Mean 95% CI No. Median Mean 95% CI
Race .09
Non-Hispanic white
Baseline 91 2.8 5.3 4.0 to 6.5 84 2.6 7.2 5.1 to 9.2
Year 1baseline 91 0.6 2.3 1.2 to 3.5 84 0.2 1.0 1.8 to 0.3
Year 2baseline 88 0.6 2.7 1.3 to 4.1 82 0.3 0.9 1.7 to 0.1
African American
Baseline 80 3.9 7.2 5.3 to 9.1 106 3.4 7.4 5.6 to 9.3
Year 1baseline 80 0.1 1.7 0.2 to 3.2 106 0.1 0.4 1.5 to 0.6
Year 2baseline 75 0.2 1.3 0.3 to 2.9 102 0.0 0.7 1.6 to 0.2
Hispanic
Baseline 37 4.3 9.5 5.3 to 13.7 33 5.6 10.0 5.0 to 14.9
Year 1baseline 37 0.1 0.2 2.0 to 1.5 33 1.4 3.2 5.3 to 1.1
Year 2baseline 29 0.2 0.5 3.4 to 2.3 26 2.1 3.7 6.3 to 1.1
Age, years .03
50-59
Baseline 74 5.0 9.0 6.6 to 11.5 94 4.6 7.9 6.0 to 9.9
Year 1baseline 74 0.1 0.4 1.0 to 1.9 94 0.6 1.4 2.3 to 0.5
Year 2baseline 69 0.5 0.2 1.8 to 1.5 91 0.7 2.0 3.0 to 0.9
60-69
Baseline 87 2.8 5.9 4.3 to 7.5 89 2.5 7.5 5.2 to 9.8
Year 1baseline 87 0.3 1.9 0.8 to 3.0 89 0.1 0.6 1.7 to 0.6
Year 2baseline 79 0.5 2.5 1.0 to 4.1 82 0.2 0.7 1.6 to 0.2
70-79
Baseline 48 1.9 5.0 3.2 to 6.8 43 3.3 7.4 4.2 to 10.6
Year 1baseline 48 0.4 2.9 1.0 to 4.8 43 0.1 1.2 2.4 to 0.1
Year 2baseline 45 1.2 3.0 1.1 to 5.0 40 0.0 0.2 1.4 to 1.0
BMI, kg/m2 .003
Normal ( 25)
Baseline 36 5.6 9.4 5.9 to 13.0 36 7.1 11.8 6.9 to 16.6
Year 1baseline 36 2.2 3.2 0.5 to 5.8 36 1.0 1.0 3.2 to 1.2
Year 2baseline 35 1.8 3.4 0.0 to 6.7 35 0.6 0.3 2.3 to 1.7
Overweight (25-30)
Baseline 74 3.8 7.7 5.7 to 9.7 71 5.2 9.7 7.0 to 12.4
Year 1baseline 74 0.9 2.8 1.5 to 4.2 71 0.6 2.1 3.2 to 0.9
Year 2baseline 67 0.8 2.7 1.0 to 4.3 67 1.0 2.6 3.9 to 1.2
Obese ( 30)
Baseline 99 2.5 5.2 3.7 to 6.7 117 2.4 5.3 4.0 to 6.5
Year 1baseline 99 0.0 0.2 0.8 to 1.1 117 0.1 0.4 1.2 to 0.3
Year 2baseline 91 0.2 0.3 0.9 to 1.5 109 0.0 0.6 1.2 to 0.0
Smoking  .001
Never
Baseline 116 3.6 7.0 5.4 to 8.6 128 3.5 7.1 5.6 to 8.7
Year 1baseline 116 0.1 1.4 0.3 to 2.4 128 0.1 0.8 1.5 to 0.1
Year 2baseline 108 0.5 2.0 0.7 to 3.2 123 0.2 1.0 1.8 to 0.2
Past
Baseline 73 2.0 6.0 4.1 to 7.9 60 5.5 8.4 5.8 to 11.0
Year 1baseline 73 0.4 2.4 0.8 to 4.0 60 1.1 1.8 2.9 to 0.7
Year 2baseline 68 0.3 2.1 0.3 to 3.9 56 0.7 1.2 2.4 to 0.0
Current
Baseline 20 5.6 8.7 4.4 to 13.1 35 1.7 8.4 3.4 to 13.5
Year 1baseline 20 0.0 0.5 1.1 to 2.0 35 0.2 0.5 3.1 to 2.1
Year 2baseline 17 1.3 1.7 4.8 to 1.4 31 0.1 1.5 3.5 to 0.5
(continued on following page)
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women (P  .09 for test of heterogeneity; Table 3). This association of
race/ethnicity with change in density by CEE versus placebo remained
after censoring for nonadherence (data not shown). The greatest in-
crease in percent density with CEE use was seen in women age 70 to 79
years (P  .03 for interaction). The increase in mammographic den-
sity in CEE versus placebo participants was greater in normal-weight
women (BMI  25.0 kg/m2) compared with heavier participants
(P  .003 for interaction), and results were similar when weight was
used as a measure of adiposity (data not shown). The increase in
percent density in CEE versus placebo participants was greater in
women who were not currently smokers compared with current or
previous smokers (P  .001), and in those with three or more births
compared with women of lower parity (P  .04). We assessed the
effect of prior hormone use on trial results by stratifying participants
into three groups—those who had never used hormone therapy, those
who used hormone therapy  1 year before random assignment, and
those with last use more than 1 year before random assignment—and
assessed change in percent density in CEE versus placebo partici-
pants in these three groups. The test for interaction was not statis-
tically significant (P  .87).
Women with a Gail risk score  1.7% experienced a greater
increase in percent density if they were randomly assigned to CEE
versus placebo compared with women with Gail risk score less than
1.7% (P  .02 for interaction; Table 4). When we investigated effects
of individual components of the Gail risk score as potential effect
modifiers (age, age at menarche, age at first full-term pregnancy,
Table 3. MPD at Baseline, Year 1, and Year 2, by Baseline Characteristics and Treatment Assignment (Continued)
Characteristic
CEE MPD Placebo MPD
P No. Median Mean 95% CI No. Median Mean 95% CI
Parity .04
Never
Baseline 20 10.6 10.8 7.0 to 14.7 22 8.4 12.6 7.2 to 18.1
Year 1baseline 20 0.3 0.2 1.9 to 1.6 22 0.4 0.8 3.3 to 1.6
Year 2baseline 20 0.5 0.5 3.0 to 2.0 22 0.4 0.9 3.0 to 1.1
1 to 2
Baseline 53 3.8 7.6 4.8 to 10.4 72 2.7 6.6 4.4 to 8.8
Year 1baseline 53 0.0 0.4 1.1 to 1.9 72 0.3 0.7 1.9 to 0.5
Year 2baseline 50 0.2 0.1 1.8 to 1.7 67 0.4 1.6 2.6 to 0.6
3 to 4
Baseline 88 3.2 6.7 4.9 to 8.6 75 3.7 8.8 6.0 to 11.6
Year 1baseline 88 0.3 2.2 0.8 to 3.7 75 0.1 1.4 2.6 to 0.2
Year 2baseline 78 0.6 2.4 0.6 to 4.2 72 0.6 1.5 2.7 to 0.3
 5
Baseline 44 2.0 4.3 2.6 to 5.9 55 3.1 5.8 4.1 to 7.5
Year 1baseline 44 0.3 2.2 0.9 to 3.6 55 0.8 1.2 2.2 to 0.2
Year 2baseline 41 0.5 2.9 1.0 to 4.8 50 0.2 0.4 1.6 to 0.9
NOTE. P values for interactions between CEE and subgroups are based on an F test from a repeated measures model with log (percent density  0.001) as
the response.
Abbreviations: MPD, mammographic percent density; BMI, body mass index; CEE, conjugated equine estrogen.
Table 4. MPD at Baseline, Year 1, and Year 2, by Treatment Assignment and Gail Risk
Group
CEE MPD Placebo MPD
No. Median Mean 95% CI No. Median Mean 95% CI
Low ( 1.7%)
Baseline 166 3.2 6.9 5.5 to 8.3 189 2.9 7.4 5.9 to 8.9
Year 1 166 3.8 8.2 6.7 to 9.7 189 2.9 6.4 5.1 to 7.7
Year 2 151 4.7 8.6 7.1 to 10.0 177 2.7 6.5 5.2 to 7.9
Year 1baseline 166 0.1 1.3 0.4 to 2.1 189 0.2 1.0 1.7 to 0.3
Year 2baseline 151 0.3 1.2 0.1 to 2.3 177 0.2 1.1 1.8 to 0.4
High
Baseline 43 3.8 6.3 4.4 to 8.2 37 5.5 9.1 5.8 to 12.3
Year 1 43 7.7 9.3 6.9 to 11.8 37 3.9 7.9 5.2 to 10.5
Year 2 42 6.7 9.6 6.7 to 12.4 36 4.8 6.8 4.4 to 9.3
Year 1baseline 43 1.3 3.0 1.0 to 5.1 37 0.3 1.2 2.8 to 0.4
Year 2baseline 42 0.9 3.4 1.0 to 5.8 36 0.5 1.5 2.7 to 0.3
NOTE. P  .02 for interaction between estrogen and menopausal hormone therapy is based on a two-sided F test from a repeated measures model with log
(percent density  0.001) as the response.
Abbreviations: MPD, mammographic percent density; CEE, conjugated equine estrogen.
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history of breast biopsy, and history of atypical hyperplasia), only age
modified the CEE effect on mammographic density (for age, see Table
3; other data not shown). None of the other baseline characteristics,
including baseline percent density (Tables 3 and 5), were statistically
significant effect modifiers of the CEE effect (at the Bonferroni ad-
justed or unadjusted 0.05 level).
DISCUSSION
In an ancillary study of the WHI randomized clinical trial, CEE re-
sulted in a higher mammographic percent density compared with
placebo after use for 1 year (2.6 percentage point difference; 95% CI,
1.0 to 2.7) and 2 years (2.9 percentage point difference; 95% CI, 0.6 to
3.1). Similar effects were observed in African American and non-
Hispanic white women.
These results, suggesting that the effect of CEE on percent
density is maintained over a 2-year period, extend the findings
from the Postmenopausal Estrogen and Progesterone Intervention
(PEPI) trial in which using CEE 0.625 mg/d for 1 year increased
mammographic density by an absolute mean of 1.2% versus a
decrease of 0.1% in placebo-treated women.8 In a small trial,
postmenopausal women randomly assigned to CEE 0.625 mg/d
(n  36) had an absolute mean increase in mammographic density
over 2 years of 1.2% versus a 1.3% decrease in women randomly
assigned to placebo (n  45; P  .01).7 A report that included
women from two trials found that postmenopausal women ran-
domly assigned to 1 mg/d of micronized 17-estradiol (n  104)
had an adjusted absolute mean increase in mammographic density
of 4.6% after 12 months versus a 0.02% increase in women as-
signed to placebo (n  93).25
Our finding of a 2.6 percentage point difference in percent den-
sity in women randomly assigned to CEE versus placebo is lower than
the 6.9 percentage point difference observed for CEE plus MPA 2.5
mg/d in WHI, where CEE plus MPA increased percent density by a
mean of 6.0 percentage points (95% CI, 4.6 to 7.5) at year 1 compared
with a mean decrease of 0.9 percentage points (95% CI, 0.2 to 1.5)
in the placebo group (P  .001), with differences largely persisting
after 2 years. These results suggest a sizeable role for progestin on
mammographic density, but our results suggest that CEE alone also
can influence mammographic density.
Unlike a prior report by Ursin et al4 of substantially lower density
in African American women, mammographic breast density was not
substantially or significantly lower in African Americans relative to
Hispanic and non-Hispanic whites in our study population. This
inconsistency could be attributed to racial/ethnic variations by age or
menopausal status, given that the Ursin et al study was in younger
women (ages 35 to 64 years) and included 44% premenopausal
women. The effect of CEE in our study on increasing percent density
was consistent between non-Hispanic whites and African American
women but was not observed in Hispanic women.
Breast cancer risk increases by 15% with each 10% increase in
percent density,3 and a meta-analysis including more than 14,000
patients confirmed a strong relationship between percent density and
breast cancer risk.26 Too few breast cancer cases (n  11) occurred in
this study to assess the relationship between the small hormone-
associated increase in mammographic density and individual breast
cancer risk.
One hypothesis is that mammographic density change may pre-
dict an intervention’s effect on breast cancer risk.9,12 Combined hor-
mone therapy increases mammographic density9 and breast cancer
risk,13 while tamoxifen reduces mammographic density27,28 and breast
cancer risk.24,29 However, raloxifene, which reduces invasive
breast cancer risk23 has not consistently been reported to de-
crease breast density.7,30 Similarly, data currently do not support an
Table 5. MPD at Baseline, Year 1, and Year 2, by Treatment Assignment and Percent Density at Baseline
Group
CEE MPD Placebo MPD
No. Median Mean 95% CI No. Median Mean 95% CI
MPD first tertile  1.5%
Baseline 66 0.5 0.6 0.5 to 0.7 77 0.5 0.6 0.5 to 0.7
Year 1 66 0.7 2.5 1.3 to 3.8 77 0.7 1.0 0.8 to 1.3
Year 2 60 0.9 2.5 1.4 to 3.5 71 0.7 1.1 0.9 to 1.4
Year 1baseline 66 0.2 2.0 0.7 to 3.2 77 0.2 0.5 0.3 to 0.6
Year 2baseline 60 0.5 1.9 0.9 to 2.9 71 0.3 0.6 0.3 to 0.9
MPD second tertile 1.5%-7.35%
Baseline 80 3.5 3.8 3.4 to 4.2 68 3.2 3.7 3.3 to 4.1
Year 1 80 3.3 5.9 4.5 to 7.2 68 3.0 3.8 2.7 to 4.8
Year 2 72 4.1 6.8 5.1 to 8.4 64 2.1 3.3 2.5 to 4.0
Year 1baseline 80 0.0 2.0 0.8 to 3.3 68 0.8 0.1 1.0 to 1.1
Year 2baseline 72 0.5 2.9 1.4 to 4.5 64 1.0 0.5 1.1 to 0.2
MPD third tertile  7.35%
Baseline 63 14.5 17.1 14.9 to 19.4 81 13.9 17.7 15.2 to 20.2
Year 1 63 16.8 17.9 15.7 to 20.1 81 11.2 14.4 12.1 to 16.6
Year 2 61 16.7 17.3 15.0 to 19.7 78 11.5 14.2 11.8 to 16.6
Year 1baseline 63 0.2 0.8 1.0 to 2.6 81 3.4 3.4 4.8 to 2.0
Year 2baseline 61 1.0 0.0 2.3 to 2.4 78 3.6 3.3 4.8 to 1.9
NOTE. P  .38 for the interactiovisuln between CEE and baseline percent density is based on an F test from a repeated measures model with log (percent
density  0.001) as the response.
Abbreviations: MPD, mammographic percent density; CEE, conjugated equine estrogen.
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effect of aromatase inhibitors on breast density,31 although these med-
ications reduce new contralateral breast cancers.24 In the WHI hor-
mone therapy trials, use of CEE plus MPA increased breast density9
and breast cancer risk,12 while CEE alone, which increased breast
density, did not increase breast cancer incidence but rather showed a
trend toward decreased risk.14 It remains to be determined whether an
individual’s change in mammographic density represents a breast
cancer risk factor for that woman.
Strengths of this report include the double-blind randomized
design; the quantitative, quality-controlled mammographic density
assessment; the 2-year follow-up period, which provides new infor-
mation on duration and the cumulative nature of CEE effects; and the
over-representation of women from several race and ethnic minority
groups. Study limitations include the evaluation of a single formula-
tion, dose and schedule of hormone therapy, and a population that is
older than women typically beginning hormone therapy.
In conclusion, use of CEE alone results in a modest but statisti-
cally significant increase in mammographic percent density which is
sustained over at least a 2-year period. The clinical significance of the
CEE effect on mammographic density remains to be determined.
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